Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raphamin for Mild COVID-19 Outpatients
NCT05364671Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
A Phase 3 trial of raphamin in coronavirus disease 2019 (COVID-19), sponsored by Materia Medica Holding. Started Apr 2022; status: completed.
02
Drugs
raphamin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05364671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364671.